Randomized phase III trial of regorafenib in metastatic colorectal cancer : analysis of the CORRECT Japanese and non-Japanese subpopulations.

• Material Type: 博士論文
• Title: Randomized phase III trial of regorafenib in metastatic colorectal cancer : analysis of the CORRECT Japanese and non-Japanese subpopulations.
• Author/Editor: 吉野, 孝之
• Author Heading: 吉野, 孝之
• Publication Date: 2017-07-19
• Publication Date (W3CDTF): 2017-07-19
• Degree Grantor: 香川大学; Kagawa University
• Date Granted: 2017-07-19
• Date Granted (W3CDTF): 2017-07-19
• Dissertation Number: 乙第280号
• Degree Type: 博士（医学）
• Conferring No. (Dissertation): 乙第280号
• Text Language Code: eng
• Subject Heading: Regorafenib; Protein kinase inhibitors; Japanese; Colorectal cancer; Clinical trial; Phase III
• Target Audience: 一般
• Note (General): 出版タイプ： P; 機関リポジトリ記載の権利情報: Copyright © 2014, The Author(s); 機関リポジトリ記載の権利情報: This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.; 機関リポジトリ記載の権利情報: https://creativecommons.org/licenses/by/4.0/
• Persistent ID (NDL): info:ndljp/pid/11122785; https://dl.ndl.go.jp/pid/11122785
• Collection (particular): 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文; https://dl.ndl.go.jp/collections/A00014
• Acquisition Basis: 博士論文（自動収集）
• Date Accepted (W3CDTF): 2018-08-03T23:36:01+09:00
• Format (IMT): PDF
• Access Restrictions: 国立国会図書館内限定公開
• Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
• Availability of remote photoduplication service: 可
• Related Material (URI): https://dl.ndl.go.jp/pid/11122785
• Periodical Title (URI): https://kagawa-u.repo.nii.ac.jp/records/311
• Is Version Of (URI): https://doi.org/10.1007/s10637-014-0154-x
• Has Version (URI): http://www.ncbi.nlm.nih.gov/pmc/articles/pmc4434855/
• Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp

• Summary, etc.: SummaryBackground In the international, phase III, randomized, double-blind CORRECT trial, regorafenib significantly prolonged overall survival (OS) v...